Stock CLDI CALIDI BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Calidi Biotherapeutics, Inc.

Equities

CLDI

US3207031010

Real-time Estimate Cboe BZX
Other stock markets
 15:12:42 2024-05-16 EDT 		5-day change 1st Jan Change
0.243 USD +4.02% Intraday chart for Calidi Biotherapeutics, Inc. +6.47% -83.64%
04-16 Calidi Biotherapeutics Prices $6.1 Million Offering MT
03-21 H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting
CI
Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director
CI
Calidi Biotherapeutics, Inc. executed a term sheet to acquire First Light Acquisition Group, Inc. from group of sellers in a reverse merger transaction.
CI
First Light Acquisition Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
First Light Acquisition Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
First Light Acquisition Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
First Light Acquisition to Take Calidi Biotherapeutics Public in SPAC Merger Deal
MT
Calidi Biotherapeutics, Inc. entered into an agreement and plan of merger to acquire First Light Acquisition Group, Inc. from group of sellers for approximately $440 million in a reverse merger transaction.
CI
First Light Acquisition Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
FIRST LIGHT ACQUISITION GROUP, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
First Light Acquisition Group Shareholders Approve Merger Date Extension; Tom Vecchiolla Named Co-CEO
MT
First Light Acquisition Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
FIRST LIGHT ACQUISITION GROUP, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
First Light Acquisition Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
FIRST LIGHT ACQUISITION GROUP, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
First Light Acquisition Group, Inc. Reports Earnings Results for the Nine Months Ended December 31, 2021
CI
FIRST LIGHT ACQUISITION GROUP, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
First Light Acquisition Group, Inc. has completed an IPO in the amount of $200 million.
CI
First Light Acquisition Group, Inc. has filed an IPO in the amount of $200 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLDI Stock
  4. News Calidi Biotherapeutics, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW